TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06528145

Intervention type: OTHER
Intervention: Evalation
Description: Post Covid Functional Scale (PCFS) was used to assess the functional status of the participants; Short Form- 36 (SF-36) questionnaire was used to assess quality of life; 30 s sit-to-stand test (30s-STS) and 6 min walk test (6 MWT) were used to assess functional capacity.

Intervention type: OTHER
Intervention: Evalation
Description: Post Covid Functional Scale (PCFS) was used to assess the functional status of the participants; Short Form- 36 (SF-36) questionnaire was used to assess quality of life; 30 s sit-to-stand test (30s-STS) and 6 min walk test (6 MWT) were used to assess functional capacity.
Study: NCT05342493

Intervention type: DRUG
Intervention: Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution
Description: The usual adult dose is 225 mg of fremanezumab (genetical recombination) administered subcutaneously as a single dose once every 4 weeks or 675 mg administered subcutaneously as a single dose once every 12 weeks.
Study: NCT04254419

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cells
Description: Natural killer cells will be taken from the patients peripheral blood cell collection. The administration of the cells will be done via an Ommaya intra-cavitary/intra-tumoral device.~Once the infusion is ready for administration patients will be admitted to the infusion unit for monitoring. NK cells will be administered through the Ommaya in approximately 2 milliliters over approximately 2 minutes; followed by 1 milliliter preservative-free normal saline flush over approximately 1 minute.
Study: NCT05914415

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Supportive care and education before surgery
Description: we will give supportive and informative education before surgery in order to increase patient' recovery rates

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive care and education before surgery
Description: we will give supportive and informative education before surgery in order to increase patient' recovery rates
Study: NCT05863013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADL-Glittre Test
Description: They will receive standard care described plus perioperative pulmonary rehabilitation, with 20 preoperative sessions and 60 postoperative sessions. Preoperative sessions will be held 2X/week, in addition to home sessions 3X/week. Each outpatient session will last 2 hours and will consist of therapeutic education, aerobic exercises, resistance training of lower limbs, upper limbs and abdominal wall and respiratory muscle training (RMT), which will include breathing pattern, positive expiratory pressure and training of inspiratory and respiratory muscles. home will last 1h, unsupervised and personalized MRT plus 30 min of aerobic walking at 60-80% of maximum HR intensity. Participants will receive a portable pedometer and HR monitor. Postoperative rehabilitation will be offered only to the IG, from 1 month after surgery, with 60 sessions divided into 24 outpatient sessions performed 2X/week and 36 home sessions 3X/week. The postoperative program will last 12 weeks.
Study: NCT05164718

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised home-based exercise
Description: 150-300 minutes of moderate intensity activity (55-75% of maximum heart rate in sinus rhythm or RPE 12-13 on the Borg Scale) or 75-150 minutes of vigorous intensity activity (75-90% of maximum heart rate or 14-16 on the Borg Scale) per week, or an equivalent combination of both, according to current general recommendations, including also those with established CVD. To maximize the potential for improvements in cardiorespiratory fitness, we encourage that at least 40-60 minutes per week (i.e. 2 sessions á 20-30 minutes) should be of vigorous intensity.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Standard management according to usual practice at the respective participating centers, including medical therapy as per guidelines. Prior to randomization all will be provided an ICM (Confirm RX™). The UC group will receive information about general PA recommendations as per guidelines at study enrollment. No further supervision is given.
Study: NCT05896540

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENFOCATE
Description: ENFOCATE is a comprehensive program of sexual education for adolescents. Its design follows the guidelines of the Intervention Mapping Approach and the orientations proposed by the Framework for Gender-Transformative Health Promotion. The intervention has a participative focus, thus the activities are designed to promote processes of knowledge, understanding, application and reflection in the adolescents. The activities aim to improve the capacity for critical thinking, increase the motivation to listen and learn actively, and to improve interpersonal abilities. The execution of the intervention uses three pillars: (i) preventive sexual behavior; (ii) gender equity; and (iii) mental health. The intervention consists of ten weekly sessions, each lasting one hour. The teams that will perform the intervention will be composed of at least two professionals of the psychosocial area (mainly psychologists, social workers and/or guidance counsellors) of the schools included in the study.
Study: NCT05065697

Intervention type: OTHER
Intervention: Brain MRI
Description: Brain MRI will be scheduled within three days before the procedure and within seven days after the procedure, as well as at 1-year follow-up. MRI will be preferably performed using a 3.0-Tesla system unless patients are pacemaker-dependent after the procedure. In such case, a 1.5-Tesla system will be used. The MRI protocol consists of standardized conventional diffusion-weighted MRI (DW-MRI), T2-FLAIR (fluid-attenuated recovery inversion) and SWI (susceptibility-weighted imaging) parameters.

Intervention type: OTHER
Intervention: Brain MRI
Description: Brain MRI will be scheduled within three days before the procedure and within seven days after the procedure, as well as at 1-year follow-up. MRI will be preferably performed using a 3.0-Tesla system unless patients are pacemaker-dependent after the procedure. In such case, a 1.5-Tesla system will be used. The MRI protocol consists of standardized conventional diffusion-weighted MRI (DW-MRI), T2-FLAIR (fluid-attenuated recovery inversion) and SWI (susceptibility-weighted imaging) parameters.
Study: NCT01311414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cafedrine/theodrenaline, urapidil
Description: Increasing blood pressure using cafedrine/theodrenalin and decreasing blood pressure using urapidil during carotid endarterectomy.
Study: NCT06212713

Intervention type: OTHER
Intervention: Questionnaire administration
Description: Questionnaire administration - version older adults and informal caregivers
Study: NCT05089604

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Immediate Release, Oral
Description: Twice Daily Tacrolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Extended Release Oral Tablet
Description: Once Daily Tacrolimus
Study: NCT06156137

Intervention type: OTHER
Intervention: Glucose variability
Description: A retrospective cohort study was conducted in hospitalized T2DM patients with NCP who were discharged or died. Clinical data and blood glucose variability parameters were collected by computer blood glucose monitoring technology (CGM). Time in range (TIR), time above target range (TAR), time below target range (TBR), mean amplitude of glycemic excursions (MAGE), absolute mean daily difference (MODD) and other indicators were used.

Intervention type: OTHER
Intervention: Glucose variability
Description: A retrospective cohort study was conducted in hospitalized T2DM patients with NCP who were discharged or died. Clinical data and blood glucose variability parameters were collected by computer blood glucose monitoring technology (CGM). Time in range (TIR), time above target range (TAR), time below target range (TBR), mean amplitude of glycemic excursions (MAGE), absolute mean daily difference (MODD) and other indicators were used.
Study: NCT06137534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation Upper Extremity Pattern
Description: Proprioceptive neuromuscular facilitation upper extremity pattern exercises will be actively applied to 20 individuals in groups of 5 in a standing position for 30 minutes in each session 3 days a week for 4 weeks.~PNF upper extremity patterns to be applied to the participants:~1. Bilateral symmetrical flexion-adduction-external rotation.~2. Bilateral symmetrical flexion-abduction-external rotation.~3. Bilateral asymmetric right: flexion-abduction-external rotation, left: flexion-adduction-external rotation.~4. Bilateral reciprocal (same diagonal) right: extension-adduction-internal rotation, left: flexion-abduction-external rotation.~5. Bilateral reciprocal (same diagonal) right: flexion-adduction-external rotation, left: extension-abduction-internal rotation.~6. Bilateral reciprocal (opposite diagonal) right: extension-adduction-internal rotation, left: flexion, adduction, external rotation.
Study: NCT05370404

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prescription by surgical team
Description: The surgical team prescribes medications to the patient

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Recommendation by surgical team
Description: The surgical team recommends the patient to take over-the-counter medications
Study: NCT03386604

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: whey protein 40 g: energy value 160 kcal; carbohydrate 10 g; 25g proteins; total fat 2.3g; saturated fats 1.1 g; trans fat 0 g; dietary fiber 0 g; sodium 157 mg; calcium 264 mg.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin energy value 160 kcal.
Study: NCT05079776

Intervention type: OTHER
Intervention: Physical length measurement
Description: Physical length will be measured and images will be collected for AI to estimate the length
Study: NCT06365268

Intervention type: OTHER
Intervention: Collection of data from the patient's medical file
Description: Collection of data from the patient's medical file. The data collected concerns a period of three years maximum.
Study: NCT06188104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trichloroacetic acid
Description: Applying Trichloroacetic acid 95 % topical solution plus acetic acid at the transformation zone or lesion (if have) of the cervix during colposcopic examination (95% topical trichloroacetic acid is used just before finishing examination, while acetic acid is used normally when perform colposcopy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trichloroacetic acid
Description: Applying Trichloroacetic acid 95 % topical solution plus acetic acid at the transformation zone or lesion (if have) of the cervix during colposcopic examination (95% topical trichloroacetic acid is used just before finishing examination, while acetic acid is used normally when perform colposcopy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trichloroacetic acid
Description: Applying Trichloroacetic acid 95 % topical solution plus acetic acid at the transformation zone or lesion (if have) of the cervix during colposcopic examination (95% topical trichloroacetic acid is used just before finishing examination, while acetic acid is used normally when perform colposcopy)
Study: NCT04650659

Intervention type: DIAGNOSTIC_TEST
Intervention: 6-minute walk test part one
Description: Measurement of: 6-minute walk distance, the modified Borg scale before and after testing and continuous measure of peripheral oxygen saturation and heart rate. The peripheral oxygen saturation will be measured continuously on three anatomical location: the forehead, an earlobe and a finger. In patients who will accept an arterial line will be placed and blood gas will be analyzed.

Intervention type: DIAGNOSTIC_TEST
Intervention: 6-minute walk test part two
Description: Measurement of: 6-minute walk distance, the modified Borg scale before and after testing and continuous measure of peripheral oxygen saturation and heart rate. The peripheral oxygen saturation will be measured continuously on three anatomical location: the forehead, an earlobe and a finger. No arterial line will be placed.

Intervention type: DIAGNOSTIC_TEST
Intervention: 1-minute sit-to-stand test
Description: Measurement of: Number of repetitions, the modified Borg scale before and after testing and continuous measure of peripheral oxygen saturation and heart rate. The peripheral oxygen saturation will be measured on the three anatomical locations mentioned above.

Intervention type: DIAGNOSTIC_TEST
Intervention: 1-minute sit-to-stand test
Description: Measurement of: Number of repetitions, the modified Borg scale before and after testing and continuous measure of peripheral oxygen saturation and heart rate. The peripheral oxygen saturation will be measured on the three anatomical locations mentioned above.

Intervention type: DIAGNOSTIC_TEST
Intervention: 4-meters gait speed test
Description: Measurement of: Time to complete the 4 meters course and calculation of the 4-meters-gait-speed.

Intervention type: DIAGNOSTIC_TEST
Intervention: 4-meters gait speed test
Description: Measurement of: Time to complete the 4 meters course and calculation of the 4-meters-gait-speed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Nailfold videocapillaroscopy
Description: Capillary density measurement of: The finger with the probe and the average of all the fingers.~NVC with 200 x magnification will be performed on the 2nd to 5th finger on both hands.

Intervention type: DIAGNOSTIC_TEST
Intervention: HR-pQCT
Description: Imaging: One arm is scanned in a 9 mm-long volume of the distal radius (110 slices), and the distal part of the 2nd to 5th finger on both hands are scanned in a 36,08 mm-long volume (440 slices) at baseline and after 1 year.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hand x-ray
Description: Imaging: Hand x-ray was performed on patients scanned with HR-pQCT, unless images were already available (≤ 1 year).

Intervention type: DIAGNOSTIC_TEST
Intervention: DEXA
Description: Imaging: A bone density (DEXA) scan was performed on patients scanned with HR-pQCT, unless it was already available (≤ 2 years).
Study: NCT05853692

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zinc Gluconate
Description: Three times a day (spray)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Bicarbonate
Description: Five times a day (rinse)
Study: NCT06488885

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Elderly care training
Description: The 60 experimental group students included in the study will have three lesson hours each week. Face-to-face training will be provided. Their consent was obtained before training was given to the experimental group. Participant Information Form and Positive and Negative Ageism Scale (PNYAÖ) will be applied as a pre-test. Trainings are 3 lesson hours, one day a week. It will be given as eight weeks and 24 hours in total. Upbeat and positive after the end of the training A posttest will be administered with the Negative Ageism Scale (PNSAS). Posttest PNSAÖ will be administered again one month after administration, and follow-up data will be obtained. Participant Information Form and Positive and Negative Ageism Scale (PNSAS) will be applied as a pre-test. Eight weeks. At the end, PNCAS will be administered again as the final test.
Study: NCT05958069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: minocycline
Description: Treatment with minocycline combined with antiepileptic drugs: After enrollment, 100mg/day (50mg specification) of minocycline hydrochloride was administered for 12 consecutive weeks;
Study: NCT04846816

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SQIN-01
Description: The drug and device combination is called SQIN-01. SQIN-01 is a combination of SQIN-Infusor and SQIN-Furosemide Investigational pump (SQIN-Infusor, medical device) intended for subcutaneous infusion of investigational product, SQINFurosemide.
Study: NCT05016297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: baricitinib 4mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 200mg twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 200mg twice a day
Study: NCT04230356

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viral Specific T-cells (VSTs) Scheduled
Description: VSTs will be infused into stem cell transplant recipients on schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viral Specific T-cells (VSTs) Treatment
Description: VSTs will be infused into stem cell transplant recipients only if viremia is detected.
Study: NCT05147701

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloRx
Description: cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Study: NCT06443606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezafibrate 400 mg in addition to UDCA therapy
Description: * Bezafibrate 400 mg and Placebo of Bezafibrate 200 mg in addition to continued UDCA at minimum dose of 12 mg/kg/d.~* Duration 96 weeks bezfibrate/ UDCA = daily oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezafibrate 200 mg in addition to UDCA therapy
Description: * Bezafibrate 200 mg and Placebo of Bezafibrate 400 mg in addition to continued UDCA at minimum dose of 12 mg/kg/d.~* Duration 96 weeks bezfibrate/ UDCA = daily oral dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in addition to UDCA therapy
Description: * Placebo of Bezafibrate 400 mg and Placebo of Bezafibrate 200 mg in addition to continued UDCA at minimum dose of 12 mg/kg/d.~* Duration 96 weeks placebo /UDCA = daily oral dose.
Study: NCT06018922

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological treatment
Description: The treatment is module-based, and the clinician are supposed to choose a small number of modules to work with depending on the patients need. The individual CBT modules are: 1) Behavioral activation, 2) Accepting thought, 3) Emotion regulation, 4) Impulse control, 5) Procrastination, 6) Relationships, 7) Problem-solving skills, 8) Structuring everyday-life, 9) Diet-Exercise-Sleep, and 10) Social anxiety. The family therapy modules are: 1) Psychoeducation about gaming, 2) Encourage other activities, 3) Positive time together, 4) Expectations and the patients abilities, 5) Making agreements in the family, 6) Emotional validation, and 7) Conflict management.
Study: NCT05393934

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High dense nutrients formula
Description: High dense nutrients formula: Powder based Infant formula with High Nutrients' Density with energy density of 100 kcal/100ml and for Pediatric Nutrition Care: A medical service to understand nutritional status, problems related to the feeding process and clinical diagnosis of the patient.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pediatric Nutrition Care (PNC)
Description: Pediatric Nutrition Care: A medical service to understand nutritional status, problems related to the feeding process and clinical diagnosis of the patient.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pediatric Nutrition Care (PNC)
Description: Pediatric Nutrition Care: A medical service to understand nutritional status, problems related to the feeding process and clinical diagnosis of the patient.
Study: NCT06355843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA
Description: PSMA is located in prostate epithelial cells and is converted to a membrane-bound protein in prostate cancer, and PSMA expression is approximately 100 to 1000 times higher in prostate cancer tissue compared to normal prostate tissue. PSMA is expressed at high levels in 95% of prostate cancer patients and is upregulated in castration-resistant prostate cancer (CRPC) and metastatic prostate cancer. PSMA expression was also increased after androgen deprivation therapy (ADT). The use of positronuclide 68Ga-labelled PSMA small molecule inhibitors can be specifically combined with prostate cancer cells, and it is important for the diagnosis of prostate cancer and its metastatic foci through PET/CT and PET/MR visualisation.~With the popularity of integrated PET/MR imaging, combining the higher resolution and morphological performance of MR imaging with the N-staging and M-staging of PET, the specificity of primary prostate cancer diagnosis can be greatly improved.
Study: NCT05556642

Intervention type: OTHER
Intervention: Biospecimen collection
Description: Clinical information and biospecimens will be collected
Study: NCT04118556

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Decidua Stroma Cells (DSC)
Description: Placenta-derived Decidua Stroma Cells. The product consists of a viable allogeneic DSCs frozen in 5% of human serum albumin (HSA) in sodium chloride (NaCl) 0.9% and 10% dimethylsulfoxide (DMSO), that is thawed and immediately diluted in 40 mL sodium chloride (NaCl) 0.9% prior to infusion. That will give a final concentration of 2.2% HSA and 2% DMSO.~DSC will be infused when steroid-refractory acute GVHD after allogenic stem-cell transplantation has been diagnosed. Two doses, one week apart, will be given to all patients. Additional doses will be used depending on response.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best available Treatment (BAT)
Description: The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, vedolizumab, ruxolitinib or infliximab. Dose and frequency will depend on label (where approved) and institutional guidelines for various BAT.
Study: NCT05853211

Intervention type: COMBINATION_PRODUCT
Intervention: Aligner and inter-arch elastics
Description: Correction of class II malocclusion by class II elastics on clear aligners
Study: NCT06516185

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: direct-printed aligner
Description: Patients will be treated with direct-printed aligners until dental alignment is achieved.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: thermoformed aligner
Description: Patients will be treated with thermoformed aligners until dental alignment is achieved.
Study: NCT06401044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 732
Description: SC injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC injection